Forte Biosciences Shares Outstanding 2016-2021 | FBRX

Forte Biosciences shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Forte Biosciences Annual Shares Outstanding
(Millions of Shares)
2020 7
2019 2
2018 1
2017 1
2016 0
2015 0
Forte Biosciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 14
2021-03-31 13
2020-12-31 7
2020-09-30 11
2020-06-30 4
2020-03-31 2
2019-12-31 2
2019-09-30 2
2019-06-30 2
2019-03-31 2
2018-12-31 1
2018-09-30 1
2018-06-30 1
2018-03-31 1
2017-12-31 1
2017-09-30 1
2017-06-30 1
2017-03-31 0
2016-12-31 0
2016-09-30 0
2016-06-30 0
2016-03-31 0
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.000B
Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29